P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Latest Information Update: 27 Mar 2023
At a glance
- Drugs Sabizabulin (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Veru Healthcare
- 22 Mar 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Dec 2022 Planned End Date changed from 26 Feb 2024 to 26 May 2024.
- 22 Dec 2022 Planned primary completion date changed from 30 Dec 2023 to 30 Mar 2024.